Avadel制药2024年第四季度GAAP每股收益$(0.05),低于预期$(0.04);销售额$50.410M,高于预期$50.033M

财报速递
03 Mar
Avadel制药公布2024年第四季度业绩,其GAAP每股收益$(0.05),低于市场预期的$(0.04)。但公司当季销售额达到$50.410M,高于市场预估的$50.033M。

以上内容来自Benzinga Earnings专栏,原文如下:

Avadel Pharmaceuticals Q4 2024 GAAP EPS $(0.05) Misses $(0.04) Estimate, Sales $50.410M Beat $50.033M Estimate

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10